Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0E0AS
|
|||
| Former ID |
DIB000957
|
|||
| Drug Name |
(S)-oxybutynin
|
|||
| Indication | Urinary incontinence [ICD-11: MF50.2; ICD-9: 788.3] | Phase 2 | [1] | |
| Company |
Sepracor
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H31NO3
|
|||
| Canonical SMILES |
CCN(CC)CC#CCOC(=O)C(C1CCCCC1)(C2=CC=CC=C2)O
|
|||
| InChI |
1S/C22H31NO3/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3/t22-/m1/s1
|
|||
| InChIKey |
XIQVNETUBQGFHX-JOCHJYFZSA-N
|
|||
| CAS Number |
CAS 119618-22-3
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:51329
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | A phase 2, randomized, double-blind, efficacy and safety study of oxybutynin vaginal ring for alleviation of overactive bladder symptoms in women. J Urol. 2014 Apr;191(4):1014-21. | |||
| REF 2 | Enantiomers of oxybutynin: in vitro pharmacological characterization at M1, M2 and M3 muscarinic receptors and in vivo effects on urinary bladder contraction, mydriasis and salivary secretion in guinea pigs. J Pharmacol Exp Ther. 1991 Feb;256(2):562-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.